^
    Back
    Association details:
    Biomarker:KIT N822K
    Cancer:Acute Myelogenous Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Proc Natl Acad Sci U S A
    Title:

    AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec

    Published date:
    01/25/2015
    Excerpt:
    Gleevec also exerted a synergic effect in apoptosis induction with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
    Secondary therapy:
    cytarabine
    DOI:
    10.1073/pnas.0408831102
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec

    Excerpt:
    Additionally, Gleevec suppressed the C-KIT activity and induced proliferation inhibition and apoptosis in cells bearing C-KIT N822K mutation or overexpression, but not in cells with D816 mC-KIT. Gleevec also exerted a synergic effect in apoptosis induction with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.